← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bluewillow Biologics, Inc.
Ann Arbor, MI
$22,647,633
Total funding
6
Grants
Funding over time
peak $5.5M · FY2010–24$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,647,633 · 6
By mechanism
N01$11,448,024 · 1
R44$7,391,139 · 2
N43$3,295,688 · 1
R41$297,250 · 1
R43$215,532 · 1
Investigators at Bluewillow Biologics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of a Nanoemulsion Adjuvant with a Vaccine for Pandemic Influenza$5,516,166
N01 · FY2013 · AI
Development of a Nanoemulsion Adjuvant$3,050,337
N01 · FY2017 · AI
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$2,916,500
N44 · FY2020 · AI
Development of a Nanoemulsion Adjuvant: HIV elective project$2,381,521
N01 · FY2016 · AI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine$998,684
R44 · FY2020 · AI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine$994,743
R44 · FY2021 · AI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine$987,515
R44 · FY2022 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$891,695
R44 · FY2024 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$872,585
R44 · FY2023 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$853,503
R44 · FY2022 · AI
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine$798,081
R44 · FY2017 · AI
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine$694,683
R44 · FY2018 · AI
Development of a Nanoemulsion Adjuvant: HIV elective project$500,000
N01 · FY2015 · AI
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$299,888
N43 · FY2019 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein$299,650
R44 · FY2020 · AI
Nanoemulsion-based vaccine for chronic hepatitis B virus$297,250
R41 · FY2010 · AI
Development of a nanoemulsion-based vaccine for chlamydia infection$215,532
R43 · FY2018 · AI
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$79,300
N44 · FY2023 · AI